Your Health. Your Family. Your Choice.
|12-17 Years||Emergency Doctor/Room||1||25%|
|TOTAL||† 6||† 150%|
|† Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table. This is the reason why the Total Count is greater than 4 (the number of cases found), and the Total Percentage is greater than 100.|
Administered by: Private Purchased by: ?
Life Threatening? Yes
Write-up: Patient developed clots/DVT in the RUE over 1-2 weeks after the Meningococeal injection. She presented to my office with large swollen arm and was sent to ED where an ultrasound showed large Subclavian DVT''s on the right
Administered by: Unknown Purchased by: ?
Life Threatening? No
Write-up: Right calf pain 5 minutes after administration of Pfizer vaccine, found to have a right lower extremity DVT after ER workup
Administered by: Pharmacy Purchased by: ?
Life Threatening? No
Write-up: received the first dose of the Pfizer COVID-19 vaccine and also recently started taking Depo-Provera. After receiving the first dose of the Pfizer COVID-19 vaccine her daughter developed a blood clot; tired and frail; feels lost and light headed; cramping pain; This is a spontaneous report from a contactable consumer (Patient''s mother). A 17-year-old female patient received first dose of BNT162B2 (BNT162B2) via an unspecified route of administration, administered in Arm Right on 03May2021 15:00 (Batch/Lot number was not reported) as 1ST DOSE SINGLE for covid-19 immunization and medroxyprogesterone acetate (DEPO-PROVERA), route of administration, start and stop date, batch/lot number and dose were not reported for contraception. The patient''s medical history and concomitant medications were not reported. The patient experienced received the first dose of the pfizer covid-19 vaccine and also recently started taking depo-provera. after receiving the first dose of the pfizer covid-19 vaccine her daughter developed a blood clot, tired and frail, feels lost and light headed and had cramping pain all on unspecified dates. It was reported that after receiving the first dose of the Pfizer COVID-19 vaccine her daughter developed a blood clot. Her daughter, who is currently on Depo Provera got her first dose of the Covid 19 vaccine. The daughter has been experiencing blood clotting and would like to further document this experience. Is also seeking medical advice to inform her daughter. Her daughter Has been on Depo Provera for 4 to 5 months. Since she had the Covid vaccine, she has been having bad blood clotting and has been having a continuous period. When she got the shot, she has been getting blood clots straight for three weeks. Patient is Tired and frail: She is a waitress, so all of this has made it hard. It started right when she got the shot and has pretty much stayed the same. She will feel like she is lost when she wakes up and is light headed from the loss of blood. It occurs when she is doing activities, like working. Patient took some Midol one day for cramping pain but it barely did anything. The action taken for medroxyprogesterone acetate was unknown. Outcome of tired and frail was not recovered. Outcome of all the other events was unknown. Information on Lot/Batch number was not available. Additional information has been requested.
Life Threatening? No
Write-up: Postoperative thrombosis; This is a spontaneous report from a contactable physician downloaded from a regulatory authority, regulatory authority number FR-AFSSAPS-NY20213284. A 18-years-old female patient received BNT162B2 (COMIRNATY, Solution for injection, Lot number- unknown), intramuscularly on 10Jun2021 as DOSE 1, SINGLE for covid-19 immunization. Patient was also taking enoxaparin sodium (LOVENOX [ENOXAPARIN SODIUM]), subcutaneous from 29Jun2021 (Batch/Lot Number: Unknown) to an unspecified date, at 4000 iU, 1x/day for thrombosis prophylaxis. Medical history included malformation venous from an unknown date, osteochondritis from an unknown date, thrombosis from an unknown date (Several episodes). Concomitant medication(s) included paracetamol (PARACETAMOL) taken for pain from 29Jul2021 to an unspecified stop date. On 02Jul2021, 23 days after beginning Comirnaty and 04days after beginning Lovenex, the patient was diagnosed with thrombosis at biopsy sites (medically significant). No thrombophilia work-up to date. The event was assessed as Non-serious. The patient had lab test on an unknown date in 2019 which included Ultrasound Doppler and results show venous dilations in lakes starting at the elbow, more marked at the ulnar border with numerous venous ectasias of the hand and all of the fingers. On 18May2021, the patient checked for D-dimers and results were 551 ?g / L. On 29Jul2021, the patient was hospitalized with a view to performing tissue biopsies for quantitative PCR, in search of the genetic determinism of the patient''s venous malformation. It was unknown if the patient received specific treatment for the event or not, but compression therapy was implemented and is effective against thrombosis, but patient compliance is poor. The second injection of COMIRNATY is scheduled for 21Jul2021. The outcome of the event was reported as thrombosis being resolved on 15Jul2021. Reporter Comment: Young 18-year-old woman who presented with thrombosis at biopsy sites 3 weeks after her first injection of Pfizer covid vaccine (COMIRNATY) and in the context of preventive anticoagulation by enoxaparin (LOVENOX). No thrombophilia assessment to date. N.B. Accountability without prejudice to the elements of investigation which could be carried out within the framework of legal or amicable compensation procedures. No follow-up attempts are possible. Information on batch/lot number cannot be obtained. No further information expected.; Reporter''s Comments: Young 18-year-old woman who presented with thrombosis at biopsy sites 3 weeks after her first injection of Pfizer covid vaccine (COMIRNATY) and in the context of preventive anticoagulation by enoxaparin (LOVENOX). No thrombophilia assessment to date.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166